Metropolitan Life Insurance Company (MetLife)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10,394
| Closed | -$4.34M | – | 2063 |
|
|
2024
Q1 | $4.34M | Sell |
10,394
-95
| -0.9% | -$40.2K | 0.19% | 94 |
|
|
2023
Q4 | $4.27M | Sell |
10,489
-190
| -2% | -$70.2K | 0.2% | 89 |
|
|
2023
Q3 | $3.71M | Sell |
10,679
-545
| -5% | -$191K | 0.19% | 93 |
|
|
2023
Q2 | $3.95M | Sell |
11,224
-276
| -2% | -$93K | 0.19% | 95 |
|
|
2023
Q1 | $3.62M | Sell |
11,500
-2,744
| -19% | -$823K | 0.19% | 103 |
|
|
2022
Q4 | $4.11M | Sell |
14,244
-699
| -5% | -$213K | 0.18% | 112 |
|
|
2022
Q3 | $4.33M | Sell |
14,943
-140
| -0.9% | -$40.3K | 0.21% | 97 |
|
|
2022
Q2 | $4.25M | Sell |
15,083
-307
| -2% | -$82.2K | 0.19% | 108 |
|
|
2022
Q1 | $4.02M | Sell |
15,390
-18,108
| -54% | -$4.3M | 0.14% | 136 |
|
|
2021
Q4 | $7.36M | Sell |
33,498
-1,335
| -4% | -$260K | 0.1% | 161 |
|
|
2021
Q3 | $6.32M | Sell |
34,833
-1,128
| -3% | -$220K | 0.09% | 176 |
|
|
2021
Q2 | $7.25M | Sell |
35,961
-9,137
| -20% | -$1.91M | 0.1% | 154 |
|
|
2021
Q1 | $9.69M | Sell |
45,098
-2,631
| -6% | -$578K | 0.14% | 116 |
|
|
2020
Q4 | $11.3M | Sell |
47,729
-1,933
| -4% | -$444K | 0.17% | 99 |
|
|
2020
Q3 | $13.5M | Sell |
49,662
-1,877
| -4% | -$518K | 0.23% | 76 |
|
|
2020
Q2 | $15M | Buy |
51,539
+1,385
| +3% | +$375K | 0.27% | 67 |
|
|
2020
Q1 | $11.9M | Sell |
50,154
-495
| -1% | -$114K | 0.24% | 74 |
|
|
2019
Q4 | $11.1M | Sell |
50,649
-261
| -0.5% | -$52.8K | 0.18% | 99 |
|
|
2019
Q3 | $8.63M | Buy |
50,910
+336
| +0.7% | +$59.4K | 0.15% | 124 |
|
|
2019
Q2 | $9.27M | Buy |
50,574
+2,632
| +5% | +$460K | 0.16% | 112 |
|
|
2019
Q1 | $8.82M | Sell |
47,942
-1,849
| -4% | -$342K | 0.16% | 107 |
|
|
2018
Q4 | $8.25M | Sell |
49,791
-230
| -0.5% | -$39.9K | 0.17% | 105 |
|
|
2018
Q3 | $9.64M | Sell |
50,021
-1,066
| -2% | -$190K | 0.16% | 105 |
|
|
2018
Q2 | $8.68M | Buy |
51,087
+759
| +2% | +$118K | 0.14% | 129 |
|
|
2018
Q1 | $8.2M | Buy |
50,328
+350
| +0.7% | +$57.2K | 0.12% | 135 |
|
|
2017
Q4 | $7.49M | Sell |
49,978
-80,736
| -62% | -$12M | 0.1% | 157 |
|
|
2017
Q3 | $19.9M | Sell |
130,714
-311
| -0.2% | -$46.8K | 0.12% | 147 |
|
|
2017
Q2 | $16.9M | Sell |
131,025
-1,710
| -1% | -$206K | 0.12% | 166 |
|
|
2017
Q1 | $14.5M | Sell |
132,735
-1,672
| -1% | -$147K | 0.1% | 191 |
|
|
2016
Q4 | $9.9M | Sell |
134,407
-3,664
| -3% | -$298K | 0.07% | 258 |
|
|
2016
Q3 | $12M | Sell |
138,071
-1,482
| -1% | -$140K | 0.09% | 221 |
|
|
2016
Q2 | $12M | Sell |
139,553
-653
| -0.5% | -$56.4K | 0.09% | 218 |
|
|
2016
Q1 | $11.1M | Sell |
140,206
-1,971
| -1% | -$178K | 0.09% | 227 |
|
|
2015
Q4 | $17.9M | Sell |
142,177
-776
| -0.5% | -$93.7K | 0.14% | 140 |
|
|
2015
Q3 | $14.9M | Sell |
142,953
-1,965
| -1% | -$252K | 0.11% | 180 |
|
|
2015
Q2 | $17.9M | Buy |
144,918
+2,057
| +1% | +$259K | 0.13% | 159 |
|
|
2015
Q1 | $16.9M | Sell |
142,861
-945
| -0.7% | -$113K | 0.12% | 170 |
|
|
2014
Q4 | $17.1M | Buy |
143,806
+1,780
| +1% | +$200K | 0.12% | 168 |
|
|
2014
Q3 | $16M | Sell |
142,026
-1,276
| -0.9% | -$121K | 0.11% | 178 |
|
|
2014
Q2 | $13.6M | Sell |
143,302
-6,161
| -4% | -$432K | 0.09% | 219 |
|
|
2014
Q1 | $10.6M | Sell |
149,463
-1,147
| -0.8% | -$90.8K | 0.07% | 271 |
|
|
2013
Q4 | $11.2M | Sell |
150,610
-2,363
| -2% | -$165K | 0.08% | 247 |
|
|
2013
Q3 | $11.6M | Sell |
152,973
-34,494
| -18% | -$2.74M | 0.09% | 228 |
|
|
2013
Q2 | $15M | Buy |
+187,467
| New | +$13.8M | 0.12% | 164 |
|
Other funds holding VRTX
Metropolitan Life Insurance Company (MetLife)'s VRTX Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 10,394 shares — an estimated $4.34M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in VRTX in Q2 2013 and held it in 44 quarters. The position peaked at $19.9M in Q3 2017. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 10,394 Vertex Pharmaceuticals shares in Q2 2024, an estimated $4.34M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 44 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Vertex Pharmaceuticals position peaked at $19.9M in Q3 2017.
- 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.